keyword
MENU ▼
Read by QxMD icon Read
search

Ranibizumab

keyword
https://www.readbyqxmd.com/read/28731494/subthreshold-micropulse-laser-reduces-anti-vegf-injection-burden-in-patients-with-diabetic-macular-edema
#1
Elad Moisseiev, Sam Abbassi, Sumeer Thinda, Joseph Yoon, Glenn Yiu, Lawrence S Morse
PURPOSE: To evaluate the efficacy of micropulse laser in the early treatment of diabetic macular edema (DME) and its associated burden of anti-vascular endothelial growth factor (VEGF) injections. METHODS: This retrospective comparative study compared a group of 19 eyes with DME treated with micropulse laser to a matched control group of 19 eyes with DME treated with ranibizumab injections without micropulse laser. Recorded parameters included previous medical and ocular history, previous and subsequent ranibizumab injections administered for DME, visual acuity (VA), central macular thickness throughout the follow-up period, and the occurrence of any complications...
July 20, 2017: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/28731052/real-world-visual-acuity-outcomes-between-ranibizumab-and-aflibercept-in-treatment-of-neovascular-amd-in-a-large-us-data-set
#2
A Lotery, R Griner, A Ferreira, F Milnes, P Dugel
PurposeTo examine 12-month real-world visual acuity outcomes and treatment patterns in neovascular age-related macular degeneration (nAMD) eyes, including those with pigment epithelial detachment (PED), receiving ranibizumab or aflibercept.Patients and methodsElectronic medical records were used to identify ranibizumab or aflibercept-treated nAMD eyes with 12 months follow-up from first prescription. The primary objective was to compare mean change in visual acuity (VA) between index and month 12, in eyes treated with ranibizumab and aflibercept to assess the non-inferiority of ranibizumab vs aflibercept using a -5 letter non-inferiority margin...
July 21, 2017: Eye
https://www.readbyqxmd.com/read/28730118/efficiency-and-safety-of-laser-photocoagulation-with-or-without-intravitreal-ranibizumab-for-treatment-of-diabetic-macular-edema-a-systematic-review-and-meta-analysis
#3
Tian-Wei Qian, Meng-Ya Zhao, Xin-Xin Li, Xun Xu
AIM: To compare the therapeutic effect and safety of laser photocoagulation along with intravitreal ranibizumab (IVR) versus laser therapy in treatment of diabetic macular edema (DME). METHODS: Pertinent publications were identified through comprehensive searches of PubMed, EMBASE, Web of Science, Cochrane Library, and ClinicalTrials.gov to identify randomized clinical trials (RCTs) comparing IVR+laser to laser monotherapy in patients with DME. Therapeutic effect estimates were determined by weighted mean differences (WMD) of change from baseline in best corrected visual acuity (BCVA) and central retinal thickness (CRT) at 6, 12, or 24mo after initial treatment, and the risk ratios (RR) for the proportions of patients with at least 10 letters of improvement or reduction at 12mo...
2017: International Journal of Ophthalmology
https://www.readbyqxmd.com/read/28730108/transfer-of-single-dose-of-intravitreal-injection-of-ranibizumab-and-bevacizumab-into-milk-of-sheep
#4
Tugba Cakmak Argun, Ozlem Yalcin Tok, Levent Tok, Gulsen Yilmaz, Fatma Meric Yilmaz, Alime Gunes, Mehmet Argun, Osman Butuner
AIM: To investigate whether single-dose intravitreal injections of bevacizumab and ranibizumab transfer into milk. METHODS: This study included lactating 12 sheep and a single 3-month old suckling lamb of each sheep. Two groups consisting of 6 sheep and their lambs were constituted; the ranibizumab group and the bevacizumab group before the administration of intravitreal injections, blood and milk samples were obtained from all sheep and, following the injections, blood and milk samples of all sheep and blood samples of all lambs were collected at regular time points...
2017: International Journal of Ophthalmology
https://www.readbyqxmd.com/read/28726562/gene-therapy-for-age-related-macular-degeneration
#5
Nicholas A Moore, Peter Bracha, Rehan M Hussain, Nuria Morral, Thomas A Ciulla
In neovascular age related macular degeneration (nAMD), gene therapy to chronically express anti-vascular endothelial growth factor (VEGF) proteins could ameliorate the treatment burden of chronic intravitreal therapy and improve limited visual outcomes associated with 'real world' undertreatment. Areas covered: In this review, the authors assess the evolution of gene therapy for AMD. Adeno-associated virus (AAV) vectors can transduce retinal pigment epithelium; one such early application was a phase I trial of AAV2-delivered pigment epithelium derived factor gene in advanced nAMD...
July 20, 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/28724817/real-world-evidence-of-safety-profile-of-intravitreal-bevacizumab-avastin-in-an-indian-scenario
#6
Prashant Jain, Jay Sheth, Giridhar Anantharaman, Mahesh Gopalakrishnan
PURPOSE: The purpose of this study was to evaluate the safety profile of intravitreal bevacizumab (Avastin) as an off-label pharmacotherapeutic agent for various ocular conditions. METHODS: Retrospective analysis was carried out on 3806 injections of 1761 patients that were administered with intravitreal bevacizumab injection at a tertiary eye care center in India. The injections were administered on a pro re nata basis for various indications such as age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO)...
July 2017: Indian Journal of Ophthalmology
https://www.readbyqxmd.com/read/28724636/predictive-imaging-biomarkers-relevant-for-functional-and-anatomical-outcomes-during-ranibizumab-therapy-of-diabetic-macular-oedema
#7
Bianca S Gerendas, Sonja Prager, Gabor Deak, Christian Simader, Jan Lammer, Sebastian M Waldstein, Tadhg Guerin, Michael Kundi, Ursula Margarethe Schmidt-Erfurth
BACKGROUND/AIMS: The objective is to identify imaging biomarkers in optical coherence tomography predicting functional/anatomical outcomes in diabetic macular oedema (DMO). METHODS: The presented study is a post hoc analysis of the RESTORE/RESTORE-extension studies. Best-corrected visual acuity (BCVA) was analysed using general estimating equation models using treatment group/morphological features as predictor variables. In addition, linear multiple regression models analysed BCVA gain up to 12 and 36 months with BCVA/morphological baseline characteristics as independent predictor variables...
July 19, 2017: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/28715811/early-response-to-ranibizumab-is-associated-with-12-month-outcome-in-diabetic-macular-edema-after-prior-macular-laser-therapy
#8
Shwu-Jiuan Sheu, Ying-Yen Lee
PURPOSE: To evaluate the efficacy of ranibizumab in persistent or recurrent diabetic macular edema (DME) after previous laser therapy. METHODS: This prospective, interventional study consisted of a 3-month period of scheduled ranibizumab treatment followed by a 9-month period of pro re nata treatment. RESULTS: A total of 21 eyes (18 patients) were included. Both best corrected visual acuity and central retinal thickness had statistically significantly improved from baseline at month 12 (p < 0...
July 18, 2017: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/28707675/submacular-hemorrhage-and-grape-like-polyp-clusters-factors-associated-with-reactivation-of-the-lesion-in-polypoidal-choroidal-vasculopathy
#9
J H Kim, Y S Chang, J W Kim, C G Kim, D W Lee
PurposeThe purpose of this study is to investigate the factors associated with reactivation of the lesion during the first year in patients with polypoidal choroidal vasculopathy (PCV) treated with intravitreal ranibizumab.Patients and methodsThis retrospective observational study included 84 eyes diagnosed with PCV and treated with 3-monthly ranibizumab injections. Only those patients who exhibited complete resolution of fluid after initial treatment and were followed up at least 12 months were included. The baseline characteristics of the patients, including their age and sex, location of the polyps, greatest linear dimensions of the lesions, largest polyp diameter, choroidal vascular hyperpermeability, submacular hemorrhages ≥1 disc area in size, presence of grape-like polyp clusters, central foveal thickness, and best-corrected visual acuity were compared between patients with and without reactivation of the lesion...
July 14, 2017: Eye
https://www.readbyqxmd.com/read/28704254/efficacy-and-safety-of-ranibizumab-for-the-treatment-of-choroidal-neovascularization-due-to-uncommon-cause-twelve-month-results-of-the-minerva-study
#10
Timothy Y Y Lai, Giovanni Staurenghi, Paolo Lanzetta, Frank G Holz, Shiao Hui Melissa Liew, Sabine Desset-Brethes, Harry Staines, Philip G Hykin
PURPOSE: To evaluate the efficacy and safety of ranibizumab 0.5 mg in adult patients with choroidal neovascularization because of an uncommon cause enrolled in the 12-month MINERVA study. METHODS: In this Phase III, double-masked study, adult (≥18 years) patients (N = 178) were randomized 2:1 to receive either ranibizumab (n = 119) or sham (n = 59) at baseline and, if needed, at Month 1 and open-label individualized ranibizumab from Month 2. Best-corrected visual acuity change from baseline to Month 2 (primary endpoint) and Month 12, treatment exposure, and safety over 12 months were reported...
July 12, 2017: Retina
https://www.readbyqxmd.com/read/28699927/short-term-outcomes-after-intravitreal-injections-of-conbercept-versus-ranibizumab-for-the-treatment-of-retinopathy-of-prematurity
#11
Enzhong Jin, Hong Yin, Xiaoxin Li, Mingwei Zhao
PURPOSE: Intravitreal injection of conbercept (IVC) is the latest applied treatment that could be used in retinopathy of prematurity (ROP) patients. The structural outcomes and recurrence of ROP among patients treated with IVC or intravitreal injection of ranibizumab (IVR) were compared. METHODS: A consecutive case series of ROP treated with IVC or IVR were retrospectively studied. The primary outcome was treatment success defined as regression of plus disease. The secondary outcomes were recurrence of plus, times of injection, and the final regression of disease...
July 7, 2017: Retina
https://www.readbyqxmd.com/read/28693011/comparaci%C3%A3-n-de-la-efectividad-de-ranibizumab-intrav%C3%A3-treo-para-el-tratamiento-del-edema-macular-diab%C3%A3-tico-en-ojos-vitrectomizados-y-no-vitrectomizados
#12
Yoshito Koyanagi, Shigeo Yoshida, Yoshiyuki Kobayashi, Yuki Kubo, Muneo Yamaguchi, Takahito Nakama, Shintaro Nakao, Yasuhiro Ikeda, Yuji Ohshima, Tatsuro Ishibashi, Kohhei Sonoda
Objetivo: Comparar la efectividad de ranibizumab intravítreo (RIV) para el tratamiento del edema macular diabético (EMD) en ojos con y sin vitrectomía previa. Procedimientos: Evaluamos de manera prospectiva la mejor agudeza visual corregida (MAVC) y el grosor macular central (GMC) tras el tratamiento con RIV durante 6 meses. Resultados: No se observaron diferencias significativas en la MAVC o GMC inicial en ninguno de los dos grupos. En el grupo no vitrectomizado (n = 15), los cambios medios en la MAVC y GMC hasta el sexto mes de tratamiento con respecto al valor inicial resultaron significativos (p < 0,01)...
July 11, 2017: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/28660277/prediction-of-anti-vegf-treatment-requirements-in-neovascular-amd-using-a-machine-learning-approach
#13
Hrvoje Bogunovic, Sebastian M Waldstein, Thomas Schlegl, Georg Langs, Amir Sadeghipour, Xuhui Liu, Bianca S Gerendas, Aaron Osborne, Ursula Schmidt-Erfurth
Purpose: The purpose of this study was to predict low and high anti-VEGF injection requirements during a pro re nata (PRN) treatment, based on sets of optical coherence tomography (OCT) images acquired during the initiation phase in neovascular AMD. Methods: Two-year clinical trial data of subjects receiving PRN ranibizumab according to protocol specified criteria in the HARBOR study after three initial monthly injections were included. OCT images were analyzed at baseline, month 1, and month 2...
June 1, 2017: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/28660080/neovascular-age-related-macular-degeneration-in-the-very-old-%C3%A2-90-years-epidemiology-adherence-to-treatment-and-comparison-of-efficacy
#14
Yousif Subhi, Torben Lykke Sørensen
PURPOSE: To investigate neovascular age-related macular degeneration (AMD) in patients aged ≥90 years from several perspectives for a comprehensive overview: prevalence, presenting characteristics, treatment adherence, reasons for discontinuation, and efficacy of antivascular endothelial growth factor (VEGF) treatment comparing Ranibizumab and Aflibercept. METHODS: In this retrospective chart review, we determined the prevalence and presenting characteristics by reviewing all data for patients referred to our department with treatment-naïve neovascular AMD...
2017: Journal of Ophthalmology
https://www.readbyqxmd.com/read/28656342/effect-of-intravitreal-ranibizumab-on-the-ocular-circulation-of-the-untreated-fellow-eye
#15
Masahiko Sugimoto, Takayasu Nunome, Rie Sakamoto, Maki Kobayashi, Mineo Kondo
PURPOSE: To evaluate the effects of unilateral intravitreal ranibizumab (IVR) on the ocular circulation of the fellow eyes. METHODS: Fifteen eyes of 15 patients with macular edema (average age 69.6 ± 11.8 years) were studied. Eleven eyes had diabetic macular edema (DME) and four eyes had macular edema associated with a branch retinal vein occlusion. Each eye received 0.5 mg of IVR. The blood circulation on the optic nerve head of the treated and untreated eyes were determined by laser speckle flowgraphy (LSFG, Softcare Co...
June 28, 2017: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/28654629/predictors-of-one-year-visual-outcomes-after-anti-vascular-endothelial-growth-factor-treatment-for-neovascular-age-related-macular-degeneration
#16
Laurent Kodjikian, Evelyne Decullier, Eric H Souied, Adeline Roux, Gilles Aulagner, Laure Huot
PURPOSE: To determine predictors of best-corrected visual acuity (BCVA) outcomes 1 year after ranibizumab or bevacizumab treatment for neovascular age-related macular degeneration, within the French Study Group Avastin versus Lucentis for neovascular age-related macular degeneration (GEFAL). METHODS: Patients aged ≥50 years presenting subfoveal neovascular age-related macular degeneration were randomized to receive ranibizumab or bevacizumab (3 monthly intravitreal injections followed by an as-needed regimen)...
June 20, 2017: Retina
https://www.readbyqxmd.com/read/28652928/ph-of-anti-vegf-agents-in-the-human-vitreous-low-impact-of-very-different-formulations
#17
Bianka Sobolewska, Peter Heiduschka, Karl-Ulrich Bartz-Schmidt, Focke Ziemssen
BACKGROUND: The aim of the study was to measure pH changes of the human vitreous caused by the intravitreal drugs bevacizumab, ranibizumab, aflibercept, and ziv-aflibercept. METHODS: Fresh human vitreous samples were obtained during core vitrectomy (23-gauge) from patients with epiretinal gliosis. Aliquots of bevacizumab, ranibizumab, aflibercept or ziv-aflibercept (2 µl) were added consecutively to 200 µl of vitreous samples or 0.9% NaCl saline. The pH was measured using a pH-sensitive microelectrode...
2017: International Journal of Retina and Vitreous
https://www.readbyqxmd.com/read/28652696/no-improvement-in-injection-frequency-or-in-visual-outcome-over-time-in-two-cohorts-of-patients-from-the-same-swedish-county-treated-for-wet-age-related-macular-degeneration
#18
Marion Schroeder, Lena Rung, Monica Lövestam-Adrian
BACKGROUND: Although ranibizumab has been used for the treatment of wet age-related macular degeneration (AMD) since 2007, real-world studies still report undertreatment resulting in a less favorable visual outcome. In this study, two different time cohorts of patients treated with ranibizumab for wet AMD in routine care were analyzed to observe whether there was a change over time regarding visual outcome, injection frequency, and quality of life (QoL). METHODS: We compared patients with treatment-naïve wet AMD in two observational follow-up cohorts 2007-2010 (n=50 patients) and 2009-2013 (n=26)...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28646440/a-comparison-of-three-different-intravitreal-treatment-modalities-of-macular-edema-due-to-branch-retinal-vein-occlusion
#19
Havva Erdogan Kaldırım, Serpil Yazgan
PURPOSE: To compare the efficacy of intravitreal injection of ranibizumab, dexamethasone implant and aflibercept for the management of macular edema (ME) related to branch retinal vein occlusion (BRVO). METHODS: This retrospective and comparative study included 62 eyes of 62 patients with BRVO and ME. Patients received one of the following treatments: 0.5 mg ranibizumab (group 1, n = 22), 0.7 mg dexamethasone implant (group 2, n = 20) and 2 mg aflibercept (group 3, n = 20)...
June 23, 2017: International Ophthalmology
https://www.readbyqxmd.com/read/28643528/modulating-release-of-ranibizumab-and-aflibercept-from-thiolated-chitosan-based-hydrogels-for-potential-treatment-of-ocular-neovascularization
#20
Miguel Moreno, Poh Yih Pow, Tan Su Teng Tabitha, Sonali Nirmal, Andreas Larsson, Krishna Radhakrishnan, Jayabalan Nirmal, Soo Tng Quah, Susana Geifman Shochat, Rupesh Agrawal, Subbu Venkatraman
BACKGROUND: This paper describes the synthesis of thiolated chitosan-based hydrogels with varying degrees of crosslinking that has been utilized to modulate release kinetics of two clinically relevant FDA-approved anti-VEGF protein drugs, ranibizumab and aflibercept. These hydrogels have been fabricated into disc shaped structures for potential use as patches on ocular surface. METHODS: Protein conformational changes and aggregation after loading and release was evaluated by circular dichroism (CD), steady-state tryptophan fluorescence spectroscopy, electrophoresis and size-exclusion chromatography (SEC)...
July 3, 2017: Expert Opinion on Drug Delivery
keyword
keyword
1767
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"